Sonoma Pharmaceuticals
SNOA
9 hedge funds and large institutions have $54.2K invested in Sonoma Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.57% less ownership
Funds ownership: 2.07% → 1.5% (-0.57%)
36% less funds holding
Funds holding: 14 → 9 (-5)
36% less capital invested
Capital invested by funds: $85.2K → $54.2K (-$31.1K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$13.2K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$25 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$31.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.88K |
| 3 |
Citigroup
New York
|
-$553 |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$82 |
| 5 |
Wells Fargo
San Francisco,
California
|
-$3 |
SNOA Hedge Fund Activity: Q4 2024 in Review
9 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q4 2024, worth a combined $54.2K — down 36% from $85.2K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SNOA and 0 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, adding an estimated $13.2K. The largest seller was Ground Swell Capital, exiting entirely with an estimated $31.9K sold.
- 9 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q4 2024, down from 14 in Q3 2024.
- Funds reported $54.2K of Sonoma Pharmaceuticals stock for Q4 2024, down 36% quarter-over-quarter.
- 0 funds opened new Sonoma Pharmaceuticals positions in Q4 2024 and 5 closed out, a net change of -5 holders.
- The largest Sonoma Pharmaceuticals buyer in Q4 2024 was UBS Group, an estimated $13.2K added.
- The largest Sonoma Pharmaceuticals seller in Q4 2024 was Ground Swell Capital, an estimated $31.9K sold.
Based on aggregated 13F filings for Q4 2024.